{
  "summary": {
    "total_customers": 36,
    "period": "2025-01-01 to 2026-01-01",
    "region": "East"
  },
  "key_insights": {
    "managed_services_premium": "Managed services customers average 70%+ GP vs 25% for time-based",
    "problem_accounts_east": [
      {"name": "Takeda Pharmaceuticals", "revenue": 701554, "gp_pct": "14.5%", "type": "time-based", "territory": "Genetown"},
      {"name": "Spectranetics", "revenue": 242075, "gp_pct": "26.4%", "type": "staffing CBA", "territory": "Mid-Atlantic"},
      {"name": "Formation Bio", "revenue": 30000, "gp_pct": "27.9%", "type": "mixed", "territory": "Genetown"},
      {"name": "Bausch Health", "revenue": 738910, "gp_pct": "29.4%", "type": "mixed", "territory": "NJ Pharma"}
    ],
    "high_margin_models": [
      {"name": "Alexion Pharmaceuticals", "revenue": 33740, "gp_pct": "100.0%", "type": "100% managed", "territory": "Genetown"},
      {"name": "Intellia Therapeutics", "revenue": 37000, "gp_pct": "96.6%", "type": "100% managed", "territory": "Genetown"},
      {"name": "Moderna", "revenue": 37200, "gp_pct": "92.8%", "type": "100% managed", "territory": "Genetown"},
      {"name": "Harmony Biosciences", "revenue": 127237, "gp_pct": "81.6%", "type": "100% managed", "territory": "Genetown"},
      {"name": "Ironwood Pharmaceuticals", "revenue": 101955, "gp_pct": "79.1%", "type": "100% managed", "territory": "Genetown"},
      {"name": "Alnylam Pharmaceuticals", "revenue": 109863, "gp_pct": "71.5%", "type": "managed services", "territory": "Genetown"},
      {"name": "Abbott Laboratories", "revenue": 1937966, "gp_pct": "47.1%", "type": "99% managed", "territory": "Mid-Atlantic"}
    ]
  },
  "regional_breakdown": {
    "east_top_10": [
      {"name": "Abbott Laboratories", "revenue": 1937966, "gp_pct": "47.1%", "territory": "Mid-Atlantic"},
      {"name": "Bausch Health", "revenue": 738910, "gp_pct": "29.4%", "territory": "NJ Pharma"},
      {"name": "Takeda Pharmaceuticals", "revenue": 701554, "gp_pct": "14.5%", "territory": "Genetown"},
      {"name": "Regeneron Pharmaceuticals", "revenue": 435511, "gp_pct": "63.0%", "territory": "NJ Pharma"},
      {"name": "Johnson & Johnson", "revenue": 408438, "gp_pct": "32.4%", "territory": "NJ Pharma"},
      {"name": "Integra LifeSciences", "revenue": 265680, "gp_pct": "37.0%", "territory": "NJ Pharma"},
      {"name": "Spectranetics", "revenue": 242075, "gp_pct": "26.4%", "territory": "Mid-Atlantic"},
      {"name": "Harmony Biosciences", "revenue": 127237, "gp_pct": "81.6%", "territory": "Genetown"},
      {"name": "Alnylam Pharmaceuticals", "revenue": 109863, "gp_pct": "71.5%", "territory": "Genetown"},
      {"name": "Ironwood Pharmaceuticals", "revenue": 101955, "gp_pct": "79.1%", "territory": "Genetown"}
    ],
    "territory_margins": {
      "Mid-Atlantic": {"revenue": 2197835, "gp_pct": "45.2%", "accounts": 8},
      "NJ Pharma": {"revenue": 2023598, "gp_pct": "40.7%", "accounts": 10},
      "Genetown": {"revenue": 1352692, "gp_pct": "43.1%", "accounts": 18},
      "Research Triangle": {"revenue": 0, "gp_pct": "N/A", "accounts": 0}
    }
  },
  "recommendations": [
    "Convert Takeda from T&M to managed services - $179K+ GP recovery potential",
    "Lift Bausch Health margin from 29.4% to 40% via service mix shift",
    "Replicate Genetown managed services model across NJ Pharma accounts",
    "Maintain 50%+ GP threshold for all Research Triangle new business",
    "Protect and expand high-margin Genetown cluster (Alexion, Intellia, Harmony, Moderna)"
  ],
  "generated_at": "2026-02-10T00:00:00Z"
}
